文献速递药物不良反应与药物警戒

mRNA新冠疫苗接种后听力损害信号的早期检测:法国药物警戒数据库的不比例分析研究

Early Detection of Hearing Impairment Signals Post-mRNA COVID-19 Vaccination: A Disproportionality Analysis Study on French Pharmacovigilance Database.
PubMed 文献 · Drug Saf · 2024-12-05

该研究基于法国药物警戒数据库,采用四种不比例分析方法按月估计2021年mRNA新冠疫苗听力损害的报告比值比(ROR),并通过多因素调整(性别、年龄、耳毒性药物及排除常见AEFI参照报告)将信号检测提前至2021年3月31日(ROR 2.67,95%CI 1.36-5.57)。加强针期间突发性感音神经性听力损失报告率估计为tozinameran 0.83/百万剂、elasomeran 4.3/百万剂,提示听力损害仍属罕见。

要点

  • 多因素调整不比例分析可较标准方法提前约4个月检测到听力损害信号。
  • 加强针期间SSNHL报告率tozinameran为0.83/百万剂,elasomeran为4.3/百万剂。
  • mRNA新冠疫苗后听力损害信号存在但事件仍属罕见。

核心结论

  • 结构良好的不比例分析可增强疫苗安全信号的早期检测,并有助于风险最小化措施的制定。
  • 根据描述性数据,mRNA新冠疫苗接种后听力损害仍属罕见。

研究设计与样本

  • 数据来源于法国药物警戒数据库,提取时间范围为2011年1月至2022年2月。
  • 病例为elasomeran和tozinameran的所有AEFI自发报告,非病例为其他疫苗的AEFI报告。
  • 2021年按月对听力损害进行不比例分析,采用四种方法估计报告比值比(ROR)。
  • 回顾性审查2022年2月2日至2023年3月1日加强针期间mRNA新冠疫苗接种后SSNHL报告,基于综合医学评估。

主要发现

  • 采用标准方法于2021年7月31日识别听力损害信号(ROR 1.50,95%CI 1.06-2.18)。
  • 多因素分析调整性别、年龄、耳毒性药物并排除常见AEFI参照报告后,最早于2021年3月31日检测到信号(ROR 2.67,95%CI 1.36-5.57)。
  • 加强针期间SSNHL报告率估计为tozinameran 0.83/百万剂,elasomeran 4.3/百万剂。

临床怎么用

  • 临床药师可关注mRNA新冠疫苗接种后听力损害相关报告,尤其在使用耳毒性药物或老年患者中。
  • 不比例分析方法可用于疫苗安全信号的早期检测,支持药物警戒实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Improving adverse events following immunisation (AEFI) detection is vital for vaccine safety surveillance, as an early safety signal can help minimize risks. In February 2022, the World Health Organization reported a preliminary signal on sudden sensorineural hearing loss (SSNHL) following coronavirus disease 2019 (COVID-19) vaccination, 54 million persons in France received at least one dose, covering 78.8% of the population within a year. OBJECTIVE: The primary objective of this study was to identify a method of disproportionality analysis capable to detect a safety signal for hearing impairment (HI) as early as possible during the initial phases of the COVID-19 vaccination campaign. Secondly, we described all cases of SSNHL reported during vaccine booster campaigns in France. METHODS: Data from January 2011 to February 2022 were extracted from the French pharmacovigilance database. Cases were all spontaneous reports of AEFI for elasomeran and tozinameran, while non-cases were AEFI reported for other vaccines. Disproportionality analysis for HI was performed monthly during 2021, to estimate a reporting odds ratio (ROR). Four different methods were used for ROR estimation. Furthermore, we reviewed cases of SSNHL following messenger RNA COVID-19 vaccinations reported during booster campaigns, from 2 February 2022 to 1 March 2023, based on a comprehensive medical evaluation. RESULTS: Using a standard methodology, we identified a signal on 31 July 2021 (ROR 1.50, 95% confidence interval [CI] [1.06-2.18]). Multivariate analysis adjusted for sex, age, ototoxic drugs and excluding reference reports of common AEFI for vaccines allowed us to detect the HI signal as early as 31 March 2021 (ROR 2.67, 95% CI [1.36-5.57]). The SSNHL reporting rate was estimated to be 0.83/1,000,000 doses for tozinameran and 4.3/1,000,000 for elasomeran during the booster campaigns. CONCLUSION: Using a well-structured disproportionality analysis could have enhanced early detection of safety signals and contribute to risk minimizing measures. According to descriptive data, HI following mRNA COVID-19 vaccines remains rare.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Boulefaa D, Bagheri H, Salvo F, et al. Early Detection of Hearing Impairment Signals Post-mRNA COVID-19 Vaccination: A Disproportionality Analysis Study on French Pharmacovigilance Database. Drug Saf. 2024. PMID: 39638989. doi:10.1007/s40264-024-01495-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。